Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29658169 | 0.90 | CTSD (0.62) | LMNAALOX15CHRM1HTTCA1 | |
| SCHEMBL322168 | 0.90 | CTSD (0.62) | LMNAALOX15CHRM1HTTCA1 | |
| SCHEMBL27789892 | 0.88 | CTSD (0.60) | LMNAALOX15HTTCA1CA2 | |
| SCHEMBL489859 | 0.87 | ALOX15 (0.60) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL28608000 | 0.87 | ALOX15 (0.60) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL29120698 | 0.86 | LMNA (0.55) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL30320256 | 0.84 | LMNA (0.62) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL5709859 | 0.84 | LMNA (0.62) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL7061561 | 0.84 | LMNA (0.53) | LMNAALOX15ARCYP3A4HPGD | |
| SCHEMBL7330142 | 0.84 | LMNA (0.61) | LMNAALOX15ARCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994005276-A1 | CYTOTOXIC COMPOUNDS | MORGAN LEE R (US) | 1994-03-17 | — | — | WO | claimed |
| US-20090186987-A1 | Processing Conditions Of Polyethylene Articles In Course Of Their Manufacture By Melt Processing | CLARIANT FINANCE (BVI) LIMITED (VG) | 2009-07-23 | — | — | US | disclosed |
| US-20090186987-A1 | Processing Conditions Of Polyethylene Articles In Course Of Their Manufacture By Melt Processing | CLARIANT FINANCE (BVI) LIMITED (VG) | 2009-07-23 | — | — | US | disclosed |
| US-20090186987-A1 | Processing Conditions Of Polyethylene Articles In Course Of Their Manufacture By Melt Processing | CLARIANT FINANCE (BVI) LIMITED (VG) | 2009-07-23 | — | — | US | disclosed |
| EP-2046883-A1 | IMPROVED PROCESSING CONDITIONS OF POLYETHYLENE ARTICLES IN COURSE OF THEIR MANUFACTURE BY MELT PROCESSING | Clariant International Ltd. (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012319-A1 | IMPROVED PROCESSING CONDITIONS OF POLYETHYLENE ARTICLES IN COURSE OF THEIR MANUFACTURE BY MELT PROCESSING | CLARIANT INTERNATIONAL LTD (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012319-A1 | IMPROVED PROCESSING CONDITIONS OF POLYETHYLENE ARTICLES IN COURSE OF THEIR MANUFACTURE BY MELT PROCESSING | CLARIANT INTERNATIONAL LTD (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-6670512-B2 | Molecular templates for metal complexation | STRYKER JEFFREY MARK (CA) | 2003-12-30 | — | — | US | disclosed |
| US-6613797-B2 | New xanthone derivatives useful for treating protozoan diseases | INTERLAB, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020183540-A1 | Substituted tetraarylethylene compounds | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA | 2002-12-05 | — | — | US | disclosed |
| EP-0888052-A4 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | INTERLAB, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001041773-A1 | XANTHONE ANALOGS FOR TREATING INFECTIOUS DISEASES AND COMPLEXATION OF HEME AND PORPHYRINS | INTERLAB, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5977077-A | PARASITICIDES; ANTIPROTOZOA AGENT | INTERLAB CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0888052-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034482-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP. (US) | 1997-09-25 | — | — | WO | disclosed |
| US-4710584-A | Derivatives of 3-benzylidene camphor, process for their preparation and their use as protective agents against UV rays and as medicaments | L'OREAL (FR) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183540-A1 | Substituted tetraarylethylene compounds | ABL1, ETV6, ALK | LMNA 3557/4885ALOX15 3539/4885AR 240/4885 |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | XPA, XDH, HMOX1 | LMNA 45/4885ALOX15 353/4885AR 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.